[1] 陈启全,李晓婷,杨勋祎,等.超声造影,剪切波弹性成像和增强CT检查诊断肝细胞癌价值分析.实用肝脏病杂志,2023,26(3):408-411. [2] Tang Z, Zhang F, Wang Y, et al. Diagnosis of hepatocellular carcinoma based on salivary protein glycopatterns and machine learning algorithms. Clin Chem Lab Med, 2022, 60(12):1963-1973. [3] Wang L, Yang X, Wang J, et al. Predictive value of PIVKA-II and AFP for the non-objective response of HBV-associated hepatocellular carcinoma after transarterial chemoembolization: a prospective study. Eur J Gastroenterol Hepatol, 2023, (12):1410-1415. [4] Zhang SG, Huang Y. Usefulness of AFP, PIVKA-II, and their combination in diagnosing hepatocellular carcinoma based on up-conversion luminescence immunochromatography. Lab Med, 2022, 53(5):488-494. [5] Yan M, Zhang X, Zhang B, et al. Deep learning nomogram based on Gd-EOB-DTPA MRI for predicting early recurrence in hepatocellular carcinoma after hepatectomy. Eur Radiol, 2023, 33(7):4949-4961. [6] Hwang SH, Rhee H. Pushing the limit of hepatocellular carcinoma diagnosis: diagnosis of subcentimetre HCC using gadoxetic acid-enhanced MRI and alpha-fetoprotein. Eur Radiol, 2024, 34(4):2269-2270. [7] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版).中华消化外科杂志,2020,19(1):1-20. [8] 中华医学会肝病学分会. 肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-792. [9] Hwang SY, Danpanichkul P, Agopian V, et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clin Mol Hepatol. 2025, 31(l):S228-S254. [10] 哈鹏,苏晓晨,付宾鹏.三期增强CT扫描联合血清AFP和VEGF水平诊断肝细胞癌患者临床研究.实用肝脏病杂志,2024,27(2):251-254. [11] 隋虎,毛佳,陈露,等.CT定量参数鉴别诊断肝局灶性结节增生与肝细胞癌的价值研究.实用肝脏病杂志,2024,27(4):611-614. [12] Gan D, Wang Y, Yang X, et al. Diagnostic value of TAP, PIVKA-II, and AFP in hepatocellular carcinoma and their prognostic value for patients treated with transarterial chemoembolization. Lab Med, 2025, 56(3):297-304. [13] Zhang S, Gao C, Wang Y, et al. Evaluating the combined diagnostic power of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II for hepatocellular carcinoma. J Gastrointest Oncol, 2025, 16(3):1157-1175. [14] 万强,赵波,王瑶瑶.血清PIVKA-II,AFP与HBV-DNA联合检测对HBV所致肝癌的诊断及预后预测价值.标记免疫分析与临床,2024,31(4):685-691. [15] Chan HLY, Vogel A, Berg T, et al. Performance evaluation of the elecsys PIVKA-II and elecsys AFP assays for hepatocellular carcinoma diagnosis. JGH Open, 2022, 6(5):292-300. [16] Yan Y, Lin XS, Ming WZ, et al. Radiomic analysis based on Gd-EOB-DTPA enhanced MRI for the preoperative prediction of Ki-67 expression in hepatocellular carcinoma. Acad Radiol, 2024, 31(3):859-869. [17] Huang Z, Zhu RH, Li SS, et al. Comparison of sonazoid-contrastenhanced ultrasound and GdEOBDTPAenhanced MRI for predicting microvascular invasion in hepatocellular carcinoma. Ultrasound Med Biol, 2024, 50(9):1339-1345. [18] Murakami T, Sofue K, Hori M. Diagnosis of hepatocellular carcinoma using Gd-EOB-DTPA MR imaging. Magn Reson Med Sci, 2022, 21(1):168-181. [19] Song M,Tao Y, He K, et al. Clear cell hepatocellular carcinoma: Gd-EOB-DTPA-enhanced MR imaging features and prognosis. Abdom Radiol (NY), 2024, 49(8):2606-2621. [20] Dopazo C, Søreide K, Rangelova E, et al.Hepatocellular carcinoma.Eur J Surg Oncol, 2024,50(1):107313. |